Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (5)
  • Open Access


    Fuzzy Logic-Based System for Liver Fibrosis Disease

    Tamim Alkhalifah1,*, Jimmy Singla2, Fahad Alurise1

    Computer Systems Science and Engineering, Vol.46, No.3, pp. 3559-3582, 2023, DOI:10.32604/csse.2023.036534

    Abstract The diagnosis of liver fibrosis (LF) is crucial as it is a deadly and life-threatening disease. Artificial intelligence techniques aid doctors by using the previous data on health and making a diagnostic system, which helps to take decisions about patients’ health as experts can. The historical data of a patient’s health can have vagueness, inaccurate, and can also have missing values. The fuzzy logic theory can deal with these issues in the dataset. In this paper, a multilayer fuzzy expert system is developed to diagnose LF. The model is created by using multiple layers of… More >

  • Open Access


    The role of baicalin on carbon tetrachloride induced liver fibrosis


    BIOCELL, Vol.46, No.4, pp. 1089-1096, 2022, DOI:10.32604/biocell.2022.013432

    Abstract The effect of the baicalin, a bio-active flavonoid extracted from Scutellaria baicalensis Georgi, on the carbon tetrachloride (CCl4) induced liver fibrosis was investigated. To compare the effect of baicalin on the liver fibrosis, five different groups of rats treated by 100, 200, and 400 mg/kg baicalin were studied. Upon CCl4 treatment, the levels of procollagen type III, aspartate aminotransferase, aminotransferase, hyaluronic acid, and hydroxyproline were significantly increased, whereas the superoxide dismutase and glutathione peroxidase content were decreased. These changes in the biochemical parameters, which are associated with liver function, were significantly attenuated by the baicalin treatment, suggesting More >

  • Open Access


    Ubiquitin-like posttranslational modifications in NAFLD progression and treatment


    BIOCELL, Vol.46, No.2, pp. 389-400, 2022, DOI:10.32604/biocell.2021.015899

    Abstract Nonalcoholic fatty liver disease (NAFLD) is a long-lasting condition that affects the liver, destroying its function. Liver injury can cause steatosis and inflammation, and further activation of hepatic stellate cells (HSCs) often leads to the development of nonalcoholic liver fibrosis. The patient with NAFLD is at risk of developing advanced liver disease and complications, such as liver failure, hepatocellular carcinoma (HCC), and portal hypertension. Although our understanding of the cellular and molecular mechanisms of NAFLD has greatly improved in recent years, treatment remains limited. Analysis and characterization of protein posttranslational modifications (PTMs) could improve our More >

  • Open Access


    FibroSURE and elastography poorly predict the severity of liver fibrosis in Fontan-associated liver disease

    Jessica L. Schachter1, Manisha Patel2, Samuel R. Horton3, A. Mike Devane4, Alex Ewing5, Gary A. Abrams6

    Congenital Heart Disease, Vol.13, No.5, pp. 764-770, 2018, DOI:10.1111/chd.12650

    Abstract Objective: As the population of patients with Fontan circulation surviving into adult‐ hood increases, hepatic cirrhosis has grown to be a significant cause of morbidity and mortality. Early detection of advanced hepatic fibrosis is imperative for proper inter‐ vention and consideration for heart or combined heart/liver transplantation. Noninvasive biomarkers and elastography have been evaluated for their diagnostic utility with variable results in the Fontan population.
    Design: The cohort included 14 patients age 26.4 SD 7.5 who underwent Fontan surgery. All patients were evaluated with FibroSURE, shear wave elastography (SWE), hepatic duplex sonography, and liver biopsy. Liver fibrosis… More >

  • Open Access


    A composite noninvasive index correlates with liver fibrosis scores in post-Fontan patients: Preliminary findings

    William N. Evans1,2, Ruben J. Acherman1,2, Michael L. Ciccolo1,3, Sergio A. Carrillo1,2, Alvaro Galindo1,2, Abraham Rothman1,2, Gary A. Mayman1,2, Elizabeth A. Adams1,2, Leigh C. Reardon1,4, Brody J. Winn5, Noel S. Yumiaco5, Lesley Shimuizu1, Yoko Inanaga1, Rowena J. Deleon1, Humberto Restrepo1,2

    Congenital Heart Disease, Vol.13, No.1, pp. 38-45, 2018, DOI:10.1111/chd.12558

    Abstract Objective: We hypothesized that clinic-based, hepatic-ultrasound, elastography measurements, either alone or in combination with other noninvasive variables, might correlate with liver-biopsy fibrosis scores in patients post-Fontan.
    Methods: Between March 2012 and February 2017, we identified patients post-Fontan that underwent elective cardiac catheterization and simultaneous transvenous hepatic biopsy. From this group, we selected patients that met inclusion criteria for liver-ultrasound, shear-wave elastography. Utilizing the results of elastography, laboratory testing, and time post-Fontan, we constructed a composite Fontan hepatic index as a sum of elastography measurements in kilopascals, model for end-stage liver disease excluding INR scores, and the square… More >

Displaying 1-10 on page 1 of 5. Per Page